drugset
drugset / Trial / NCT05074147

Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)

NCT05074147 ↗

Phase 3 Withdrawn Tourcoing Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this clinical study is to compare the efficacy and tolerance of 3 versus 6 weeks of antibiotherapy in patients with diabetic foot osteomyelitis treated medically.

Timeline

Start
2022-05-01
Primary completion
2024-11
Completion
2026-11

Outcome

Outcome not reported

Stopped (Business): “logistical and financial problems”

Drugs

EvaluationDrugModalityDoseRoute
Background Cefotaxim Unknown 1 g Intravenous
Background Cefotaxim Unknown 2 g Intravenous
Background Ceftasidim Unknown 2 g —
Background Ceftriaxone Other / unclassified 1 g Intravenous
Background Ceftriaxone Other / unclassified 2 g Intravenous
Background Ciprofloxacin Small molecule 400 mg Intravenous
Background Ciprofloxacin Small molecule 750 mg Intravenous
Background Ciprofloxacin Small molecule 1 g Intravenous
Background Clindamycin Unknown 600 mg —
Background Clindamycin Unknown 900 mg —
Background Doxycycline Small molecule 200 mg —
Background Fusidic Acid Unknown 500 mg —
Background Levofloxacin Small molecule 500 mg Oral
Background Levofloxacin Small molecule 1 g Oral
Background Minocyclin Unknown 100 mg —
Background Ofloxacin Small molecule 200 mg Oral
Background PRISTINAMYCIN Unknown 1 g —
Background Rifampicin Small molecule 10 mg/kg Other
Background Teicoplanin Other / unclassified 10 mg/kg —
Background trimethoprim-sulfamethoxazole Unknown 160 mg —
Background trimethoprim-sulfamethoxazole Unknown 800 mg —

Indications

osteomyelitis